ACP Revenue and Competitors

Location

N/A

Total Funding

Food

Industry

Estimated Revenue & Valuation

  • ACP's estimated annual revenue is currently $46.6M per year.(i)
  • ACP's estimated revenue per employee is $297,000

Employee Data

  • ACP has 157 Employees.(i)
  • ACP grew their employee count by 11% last year.

ACP's People

NameTitleEmail/Phone
1
VP SalesReveal Email/Phone
2
VP FinanceReveal Email/Phone
3
VP Supply ChainReveal Email/Phone
4
Director ManufacturingReveal Email/Phone
5
Director Design EngineeringReveal Email/Phone
6
Director QualityReveal Email/Phone
7
Director Sales - EastReveal Email/Phone
8
Director Global Chain SalesReveal Email/Phone
9
Director Marketing And Product ManagementReveal Email/Phone
10
Director Key Account Sales & Culinary ServicesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$164.7M4882%N/AN/A
#2
$16.3M6710%N/AN/A
#3
$870.9M23047%N/AN/A
#4
$29.7M1102%N/AN/A
#5
$46.6M15711%N/AN/A
#6
$41.6M1403%N/AN/A
#7
$172.8M5122%N/AN/A
#8
$4.7M25-7%N/AN/A
#9
$53.5M1802%N/AN/A
#10
$79.3M2676%N/AN/A
Add Company

What Is ACP?

ACP, Inc. manufactures and distributes commercial high speed combination ovens and microwaves under the Amana® Commercial and Menumaster® Commercial brands, two of the most recognized and respected brands in the foodservice industry. Our headquarters and manufacturing facility is in the heartland of the United States, yet our reach is global through our international distribution and our affiliation as part of The Ali Group of Foodservice Equipment Companies.

keywords:Food & Beverages

N/A

Total Funding

157

Number of Employees

$46.6M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ACP News

2022-04-20 - Acadia Pharma Shares Fall 6%; ACP-044 Trial Misses Primary Endpoint

Shares of Acadia Pharmaceuticals Inc. were lower in Monday's late-trading session, after the company said a Phase 2 trial of its ACP-044 to...

2022-04-20 - Acadia Pharmaceuticals Announces Top-Line Results from ...

ACP-044 is a non-opioid, novel, first in class, redox modulator investigational drug in development for the treatment of acute and chronic pain.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M159-1%N/A
#2
$57.9M1625%N/A
#3
$59.3M1672%N/A
#4
$55.2M1733%N/A
#5
$19.5M1775%N/A